DURATION-GC: FLOT Plus Durvalumab and TS-1 Plus Durvalumab for Resectable Gastric Cancer

To address regional disparity, the investigators propose a tailored perioperative strategy for East Asian patients, combining neoadjuvant FLOT plus durvalumab, followed by adjuvant TS-1 plus durvalumab. This approach seeks to balance efficacy, immunologic synergy, and treatment tolerability, offering a more practical regimen for Eastern populations.

NCT Number	NCT07757191
Lead Sponsor	Taipei Veterans General Hospital, Taiwan
Conditions	Resectable Gasrtic Cancer
Enrollment	35 participants
Start Date	2026-09
Primary Completion	2028-09 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-11